PTC THERAPEUTICS INC (PTCT) Stock Fundamental Analysis
NASDAQ:PTCT - Nasdaq - US69366J2006 - Common Stock - Currency: USD
Overall PTCT gets a fundamental rating of 6 out of 10. We evaluated PTCT against 562 industry peers in the Biotechnology industry. PTCT has an average financial health and profitability rating. PTCT is growing strongly while it is still valued neutral. This is a good combination! This makes PTCT very considerable for growth investing!
1. Profitability
1.1 Basic Checks
PTCT had positive earnings in the past year.
PTCT had a positive operating cash flow in the past year.
PTCT had negative earnings in each of the past 5 years.
In the past 5 years PTCT always reported negative operating cash flow.
1.2 Ratios
PTCT has a better Return On Assets (22.40%) than 98.75% of its industry peers.
The Return On Invested Capital of PTCT (33.50%) is better than 99.47% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 22.4% | ||
| ROE | N/A | ||
| ROIC | 33.5% |
ROA(3y)-29.05%
ROA(5y)-26.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 33.55%, PTCT belongs to the top of the industry, outperforming 97.50% of the companies in the same industry.
PTCT has a better Operating Margin (49.27%) than 99.64% of its industry peers.
PTCT has a Gross Margin of 96.87%. This is amongst the best in the industry. PTCT outperforms 96.08% of its industry peers.
In the last couple of years the Gross Margin of PTCT has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 49.27% | ||
| PM (TTM) | 33.55% | ||
| GM | 96.87% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y-0.66%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so PTCT is creating value.
PTCT has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, PTCT has more shares outstanding
PTCT has a worse debt/assets ratio than last year.
2.2 Solvency
PTCT has an Altman-Z score of 1.82. This is not the best score and indicates that PTCT is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 1.82, PTCT is in the better half of the industry, outperforming 72.37% of the companies in the same industry.
The Debt to FCF ratio of PTCT is 3.47, which is a good value as it means it would take PTCT, 3.47 years of fcf income to pay off all of its debts.
PTCT has a Debt to FCF ratio of 3.47. This is amongst the best in the industry. PTCT outperforms 93.94% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.47 | ||
| Altman-Z | 1.82 |
ROIC/WACC4.22
WACC7.93%
2.3 Liquidity
A Current Ratio of 3.89 indicates that PTCT has no problem at all paying its short term obligations.
PTCT has a Current ratio of 3.89. This is comparable to the rest of the industry: PTCT outperforms 45.81% of its industry peers.
PTCT has a Quick Ratio of 3.85. This indicates that PTCT is financially healthy and has no problem in meeting its short term obligations.
PTCT's Quick ratio of 3.85 is in line compared to the rest of the industry. PTCT outperforms 47.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.89 | ||
| Quick Ratio | 3.85 |
3. Growth
3.1 Past
PTCT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 189.25%, which is quite impressive.
PTCT shows a strong growth in Revenue. In the last year, the Revenue has grown by 91.12%.
PTCT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 21.32% yearly.
EPS 1Y (TTM)189.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%936.67%
Revenue 1Y (TTM)91.12%
Revenue growth 3Y14.42%
Revenue growth 5Y21.32%
Sales Q2Q%459.73%
3.2 Future
PTCT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.43% yearly.
PTCT is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.74% yearly.
EPS Next Y181.26%
EPS Next 2Y22.09%
EPS Next 3Y23.98%
EPS Next 5Y21.43%
Revenue Next Year93.99%
Revenue Next 2Y2.23%
Revenue Next 3Y9.67%
Revenue Next 5Y13.74%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 8.78, which indicates a very decent valuation of PTCT.
Based on the Price/Earnings ratio, PTCT is valued cheaper than 97.68% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 25.82. PTCT is valued rather cheaply when compared to this.
The Forward Price/Earnings Ratio is negative for PTCT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.78 | ||
| Fwd PE | N/A |
4.2 Price Multiples
98.93% of the companies in the same industry are more expensive than PTCT, based on the Enterprise Value to EBITDA ratio.
PTCT's Price/Free Cash Flow ratio is rather cheap when compared to the industry. PTCT is cheaper than 99.11% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.23 | ||
| EV/EBITDA | 3.79 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as PTCT's earnings are expected to grow with 23.98% in the coming years.
PEG (NY)0.05
PEG (5Y)N/A
EPS Next 2Y22.09%
EPS Next 3Y23.98%
5. Dividend
5.1 Amount
No dividends for PTCT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
45.93
+0.41 (+0.9%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners102.05%
Inst Owner Change2.64%
Ins Owners0.74%
Ins Owner Change3.97%
Market Cap3.62B
Analysts74.55
Price Target63.75 (38.8%)
Short Float %6.51%
Short Ratio3.98
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2260.84%
Min EPS beat(2)-221.32%
Max EPS beat(2)4742.99%
EPS beat(4)2
Avg EPS beat(4)1127.12%
Min EPS beat(4)-221.32%
Max EPS beat(4)4742.99%
EPS beat(8)3
Avg EPS beat(8)526.16%
EPS beat(12)3
Avg EPS beat(12)339.46%
EPS beat(16)4
Avg EPS beat(16)251.33%
Revenue beat(2)1
Avg Revenue beat(2)287.62%
Min Revenue beat(2)-10.09%
Max Revenue beat(2)585.33%
Revenue beat(4)2
Avg Revenue beat(4)146.44%
Min Revenue beat(4)-10.09%
Max Revenue beat(4)585.33%
Revenue beat(8)4
Avg Revenue beat(8)74.22%
Revenue beat(12)7
Avg Revenue beat(12)50.19%
Revenue beat(16)10
Avg Revenue beat(16)39.08%
PT rev (1m)-1.24%
PT rev (3m)8.29%
EPS NQ rev (1m)3.36%
EPS NQ rev (3m)17.95%
EPS NY rev (1m)256.51%
EPS NY rev (3m)791.72%
Revenue NQ rev (1m)4.09%
Revenue NQ rev (3m)4.08%
Revenue NY rev (1m)118.63%
Revenue NY rev (3m)72.57%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.78 | ||
| Fwd PE | N/A | ||
| P/S | 2.04 | ||
| P/FCF | 5.23 | ||
| P/OCF | 5.24 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 3.79 |
EPS(TTM)5.23
EY11.39%
EPS(NY)-3.06
Fwd EYN/A
FCF(TTM)8.79
FCFY19.13%
OCF(TTM)8.77
OCFY19.09%
SpS22.48
BVpS-2.36
TBVpS-4.9
PEG (NY)0.05
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 22.4% | ||
| ROE | N/A | ||
| ROCE | 42.4% | ||
| ROIC | 33.5% | ||
| ROICexc | 2102.85% | ||
| ROICexgc | N/A | ||
| OM | 49.27% | ||
| PM (TTM) | 33.55% | ||
| GM | 96.87% | ||
| FCFM | 39.09% |
ROA(3y)-29.05%
ROA(5y)-26.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y-0.66%
F-Score8
Asset Turnover0.67
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.47 | ||
| Debt/EBITDA | 2.39 | ||
| Cap/Depr | 4.95% | ||
| Cap/Sales | 0.08% | ||
| Interest Coverage | 202.52 | ||
| Cash Conversion | 76.77% | ||
| Profit Quality | 116.5% | ||
| Current Ratio | 3.89 | ||
| Quick Ratio | 3.85 | ||
| Altman-Z | 1.82 |
F-Score8
WACC7.93%
ROIC/WACC4.22
Cap/Depr(3y)15.16%
Cap/Depr(5y)26.1%
Cap/Sales(3y)2.81%
Cap/Sales(5y)3.67%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)189.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%936.67%
EPS Next Y181.26%
EPS Next 2Y22.09%
EPS Next 3Y23.98%
EPS Next 5Y21.43%
Revenue 1Y (TTM)91.12%
Revenue growth 3Y14.42%
Revenue growth 5Y21.32%
Sales Q2Q%459.73%
Revenue Next Year93.99%
Revenue Next 2Y2.23%
Revenue Next 3Y9.67%
Revenue Next 5Y13.74%
EBIT growth 1Y684.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-1.96%
EBIT Next 3Y70.02%
EBIT Next 5YN/A
FCF growth 1Y315.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y339.54%
OCF growth 3YN/A
OCF growth 5YN/A